Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.81ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.81NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.81NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
HV.1.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
HV.1.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
HV.1.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FL.2.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FL.2.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FL.2.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
KK.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
KK.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
KK.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.3.17ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.3.17NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.3.17NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FG.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FG.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FG.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GN.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GN.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GN.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FY.1.2.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FY.1.2.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FY.1.2.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.413ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.413NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.413NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FY.5.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FY.5.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FY.5.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
JD.1.2.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
JD.1.2.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
JD.1.2.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.268ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.1.268NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.1.268NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.409ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.409NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.409NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FG.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FG.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FG.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
KV.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
KV.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19646.7China
KV.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GK.1.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
GK.1.6NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
GK.1.6NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.2.31ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.2.31NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used